Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
PZ HTL SA

Bruker and 3M Collaborate for MALDI Imaging for Cancer Research

By BiotechDaily International staff writers
Posted on 14 Jun 2013
Bruker Corp. (Billerica, MA, USA) reported that it has signed an exclusive patent license agreement with 3M Company (Maplewood, MN, USA), which allows Bruker to include 3M patented technology related to matrix-assisted laser desorption ionization (MALDI) mass spectrometry imaging.

The licensed 3M patents are directed to a technique for performing mass spectrometry analysis on proteins in tissue that has been preserved in paraffin. The technology enables researchers to study formalin-fixed, paraffin-embedded (FFPE) tissue for drug development and life-science research.

MALDI imaging has been increasingly utilized to analyze clinically pertinent tissues such as tumor biopsies. The molecular phenotypes visualized by MALDI imaging have been demonstrated to correlate with parameters such as disease status or patient outcome, and have been effectively applied to the categorization of tissue samples.

MALDI imaging was first developed for the analysis of fresh, frozen tissue sections, however, the analysis of preserved FFPE tissue sections is becoming increasingly important due to methodological enhancements. In the MALDI imaging community, it is widely accepted that a meaningful analysis of FFPE tissue requires a pretreatment called antigen-retrieval.
Dr. Sören-Oliver Deininger, market manager for MALDI imaging at Bruker, stated, “The interest in the analysis of FFPE tissue by MALDI imaging is increasing strongly. Bruker has developed innovative technology to make MALDI imaging viable in histopathology by the integration of virtual microscopy and the possibility to classify tissue based on the molecular phenotypes [class-imaging]. Our license agreement with 3M shows our ongoing commitment to the MALDI imaging field, and gives our customers the necessary freedom to conduct their research and advance the field.”

MALDI imaging is suited to analyze biomarkers in tissue samples. By enabling histologic correlation of molecular phenotypes and correlation of molecular signals to clinical endpoints, the technology is an effective application for cancer research. It directly images metabolites, peptides, proteins, lipids, and drugs in FFPE samples with no antibodies, probes, fluorescent dyes, or radiolabels needed.

However, analysis can be complex, tiresome, and difficult to interpret. Bruker has developed special software that supports the entire workflow, including statistical analysis, providing simple and automated interpretation and reporting of results. This new agreement with 3M supports the continued development and use of this important enabling application.


Related Links:

Bruker
3M Company



Channels

Genomics/Proteomics

view channel
Image: The TheraCyte cell encapsulation device (Photo courtesy of TheraCyte, Inc.).

Encapsulated Human-Insulin-Producing Progenitor Cells Cure Diabetes in Mouse Model

A breakthrough system that allows subcutaneous implantation of encapsulated immature pancreatic cells (beta progenitor cells) was shown to produce enough insulin to correct the symptoms of diabetes in a mouse model.... Read more

Drug Discovery

view channel
Image: Chitosan is derived from the shells of shrimp and other sea crustaceans, including Alaskan pink shrimp, pictured here (Photo courtesy of NOAA - [US] National Oceanic and Atmospheric Administration).

Chitosan Treatment Clears the Way for Antibiotics to Eliminate Recurrent Urinary Tract Infections

Recurrent urinary tract infection was successfully resolved in a mouse model by treatment with the exfoliant chitosan followed by a round of antibiotics. Bacterial urinary tract infection (UTI), most... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more

Lab Technologies

view channel
Image: Diagram of the apparatus for testing drug solubility (Photo courtesy of the University of Huddersfield).

Novel Apparatus Mimics the Human Digestive System for Oral Drug Studies

A team of British drug developers has created an instrument that mimics the human digestive system, which will allow them to accurately determine how orally-administered medications are dissolved and then absorbed.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.